Celsius Therapeutics
ClosedOn a quest to leverage the power of single cell genomics
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- celsiustx.com
- Total Funding
- $148.0M
- Last Round
- $83.0M Series BMar 2022
- Rounds
- 2
About
Celsius Therapeutics was a biotechnology company that leveraged single-cell RNA sequencing and genomic analysis to identify novel drug targets and develop precision medicines for complex diseases including autoimmunity and cancer. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company built a human tissue-based platform combining scRNA-seq with machine learning to characterize disease biology at the cellular level. Celsius was acquired by AbbVie in June 2024.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Jun 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biopharmaceutical services company
Specialty pharmaceutical company
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.